If you would like to discuss material transfer issues, please contact Howard G. Zaharoff. Our university is a signatory to the Uniform Biological Material Transfer Agreement (UBMTA) Master Agreement (UBMTA), a contractual mechanism published by NIH on behalf of PHS to facilitate the transfer of biological material between academic institutions. For institutions that have accepted the terms of the UBMTA master contract, it is not necessary to negotiate individual terms for any transfer of a biological material. Instead, a letter of execution is implemented, which refers to both the biological material, the supply agency and the host institution. Where possible, the Clinical/Corporate Contracts Services team will use UBMTA to expedite the transfer of applicable biological materials. Outgoing MTAs allow CU Boulder researchers to make materials available to recipients while protecting CU Boulder`s Intellectual Property (IP) protection. In order to facilitate broad access to research resources, the university encourages its researchers to consider depositioning university-owned research tools at permanent storage sites for further distribution. Examples may be entities like Jackson Labs or Addgene. Researchers who identify an interest repository that accepts materials can use MyRA to send an MTA (transfer direction – shipment) to the Office of Sponsored Programs for such filings. For any questions about deposits, please contact 412-624-7419. Most institutions do not levy similar licenses or royalties for the non-commercial use of their unique biological materials.
Risk management should be proportionate to the nature and likelihood of benefits: institutional contract staff should assess the existence or likelihood of the following risk categories against the likely benefits of the institution and/or its researchers, and use MTAs or simpler agreements accordingly. First, the risks relate to safety in the use of materials; ensure, for example, that scientifically quality materials are not used in human research or that materials are used in accordance with ethical standards. A second category of risk is legal: the inappropriate use of reagents may result in legal action by victims against entities; Third parties may claim that the material violates their intellectual property rights or that the materials provided are not of the quality claimed by the distributor. A third category of risk is reputation: MTAs may require adequate recognition of the author or distributor archives in subsequent publications or other research results, in order to promote the reputation of the source and provide a measure of the value of the material.